Related Experiment Video
Updated: Jan 7, 2026

Assessment of Child Anthropometry in a Large Epidemiologic Study
Published on: February 2, 2017
Early-Life Nutritional Determinants of Pediatric MASLD
1Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
Insights
Pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) has unique origins, starting in utero. Early life nutrition and maternal health significantly impact offspring liver fat, highlighting critical intervention windows.
Area of Science:
- Hepatology and Metabolic Disorders
- Pediatric Gastroenterology
- Developmental Nutrition
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread liver condition affecting both children and adults.
- Pediatric MASLD presents distinct features compared to adult forms, suggesting unique developmental pathways.
- Intrauterine and early-life factors are increasingly recognized as crucial in the pathogenesis of pediatric MASLD.
Purpose of the Study:
- To review and synthesize evidence on prenatal, postnatal, and early childhood nutritional exposures linked to pediatric MASLD.
- To emphasize the critical early-life windows for potential interventions against pediatric MASLD.
- To understand the multi-hit continuum contributing to MASLD development from in utero.
Main Methods:
- Narrative review of existing human cohort studies and mechanistic model systems.
- Synthesis of converging evidence on nutritional exposures and hepatic lipid accumulation.
- Focus on prenatal (maternal health, diet), postnatal (feeding practices), and early childhood (diet quality) factors.
Main Results:
- Maternal factors like obesity and gestational diabetes are associated with increased offspring hepatic steatosis.
- Postnatal feeding (breastfeeding vs. formula with added sugars) and early childhood diets influence MASLD susceptibility.
- Combined genetic and environmental factors contribute to the heterogeneity of pediatric MASLD.
Conclusions:
- Pediatric MASLD development is a complex continuum influenced by early-life exposures.
- Nutritional interventions during pregnancy and early childhood are vital for preventing MASLD.
- Targeting early-life windows offers a promising strategy to reduce the global burden of pediatric MASLD.
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder in both children and adults. Pediatric MASLD, however, is not simply an early form of adult disease, as it exhibits distinct developmental, histological, and metabolic features. Emerging evidence suggests that these characteristics arise from a complex, multi-hit continuum that begins in utero. Maternal obesity, gestational diabetes, and poor diet quality during pregnancy have been associated with greater hepatic steatosis in offspring, raising the possibility that intrauterine exposure to dyslipidemia, hyperglycemia, and elevated free fatty acid flux may contribute to early hepatic lipid deposition. After birth, feeding behaviors such as a prolonged breastfeeding appear protective, whereas formula feeding, especially high added-sugar formulations, may accelerate rapid weight gain and increase susceptibility to later steatosis. Early childhood diets high in added sugars, saturated fats, and ultra-processed foods may further promote hepatic lipogenesis and inflammation and interact with underlying genetic susceptibility. Given the heterogeneity of available human cohort studies and mechanistic model systems, this narrative review summarizes converging evidence from prenatal, postnatal, and early childhood nutritional exposures and their relationship to offspring hepatic lipid accumulation, emphasizing early-life windows for intervention to reduce the burden of pediatric MASLD.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Environmental Influences on Intelligence
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Nature and Nurture
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion

